North America Metastatic Cancer Drugs Market Forecast to 2028

North America Metastatic Cancer Drugs Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous and Intramuscular), Drug Class (HER2 Inhibitors, Immune Checkpoint Inhibitors, PARP Inhibitors, Kinase Inhibitors, and Others), Product (Branded, Generics, and Biosimilars), and End User (Hospital, Specialty Clinic, and Others)

Report Code : BMIRE00025361 | Region : North America | Industry : Pharmaceuticals | Published Date : 15/Jul/2022

The North America metastatic cancer drugs market is expected to reach US$ 27,989.14 million by 2028 from US$ 21,414.73 million in 2021; it is estimated to grow at a CAGR of 3.9% from 2021 to 2028.

A few most common cancer types include lung cancer, breast cancer, colon cancer, rectum cancer, and prostate cancer. The condition develops in ~400,000 children every year. Carcinogenic infections, including Helicobacter pylori, hepatitis B virus, human papillomavirus (HPV), hepatitis C virus, and Epstein-Barr virus, caused ~13% of cancer cases in 2018 regionally. The International Agency for Research on Cancer (IARC) projects that the number of new cancer cases and cancer-related deaths worldwide would grow ~1.6–1.7 fold to reach 29.5 million by 2040 from 16.4 million in 2018. Further, according to the American Society of Clinical Oncology, in 2021, ~290,560 people (287,850 women and 2,710 men) in the US were diagnosed with invasive breast cancer. Breast cancer in females has now surpassed lung cancer as the most commonly diagnosed cancer worldwide. ~2,261,419 women were diagnosed with breast cancer in 2020.

All the observations recorded about cancer in the US over the past several decades show that metastatic cancer accounts for up to 90% of all cancer deaths each year. These numbers have motivated doctors and researchers to find new ways to treat metastasis, which occurs when cancer spreads beyond its point of origin. In the US, 6% of women were diagnosed with metastatic breast cancer in the first diagnosis. Such rise in the prevalence of cancer and metastatic cancer is driving the growth of the metastatic cancer drug market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the metastatic cancer drugs market growth in the coming years. The market is expected to grow at a good CAGR during the forecast period.

North America Metastatic Cancer Drugs Market Revenue and Forecast to 2028 (US$ Million)

North America Metastatic Cancer Drugs Market Segmentation

The North America metastatic cancer drugs market is segmented on the basis of cancer type, route of administration, drug class, product, and end user. Based on cancer type, the market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the market is bifurcated into intravenous and intramuscular. Based on drug class , the North America metastatic cancer drugs market is segmented into HER2 inhibitors, immune checkpoint inhibitors, parp inhibitors, kinase inhibitors, and others. Based on product, the market is segmented into branded, generics, and biosimilars . Based on end user, the market is segmented into hospital, specialty clinic, and others. By country, the North America metastatic cancer drugs market is segmented into the US, Mexico, and Canada.

North America Metastatic Cancer Drugs Market – Companies Mentioned

AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; F. HOFFMANN-LA ROCHE LTD.; Novartis AG; Astrazeneca; Eli Lilly and Company; MERCK KGaA ; Pfizer Inc. (Arena Pharmaceutical GmbH); and Johnson and Johnson Services, Inc. are among the leading companies in the North America metastatic cancer drugs market.

PARP Inhibitors segment has the Largest Share of Drug Class in the North America Metastatic Cancer Drug Market during 2019–2028

According to our latest study on “North America Metastatic Cancer Drug Market Forecast to 2028 – COVID-19 Impact and Analysis – by Cancer Type, Route of Administration, Drug Class, Product, End User” the market is projected to reach US$ 27,989.14 million by 2028 from US$ 21,414.73 million in 2021; it is expected to grow at a CAGR of 3.9% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high prevalence of cancer and government initiatives to support developments in cancer treatment. However, complex technological process and high initial investment hampers the market growth.

Based on drug class, has been segmented into HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others. In 2021, the PARP inhibitors segment accounted for the largest share of the market; it is further expected to continue its dominance over the forecast period. This class of drugs are used to prevent the cell from damage repair and dies. Thus, it helps in the slowing down the growth of cancer cells and prevents from spreading to other body parts. On the other hand, HER2 inhibitors drug class segment is expected to register the highest CAGR in the metastatic cancer drugs market during 2021–2028.

AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., Novartis AG, Astrazeneca, Eli Lilly and Company, MERCK KGaA, Pfizer Inc. (Arena Pharmaceutical GmbH), Johnson and Johnson Services, Inc., are among the leading companies in the North America metastatic cancer drug market .The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

The market for North America metastatic cancer drugs market is segmented into cancer type, route of administration, drug class, product, and end user. Based on cancer type, the market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the North America metastatic cancer drugs market is segmented into intravenous, and intramuscular. Based on drug class, the market is segmented into HER2 inhibitors, immune checkpoint inhibitors, parp inhibitors, kinase inhibitors, and others. Based on product, the market is segmented into branded, generics and biosimilars. Based on end user, the North America metastatic cancer drugs market is segmented into hospital, specialty clinic, and others. By Country, the North America metastatic cancer drugs market is segmented into US, Mexico and Canada.

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 North America Metastatic Cancer Drugs Market – By Cancer Type

1.3.2 North America Metastatic Cancer Drugs Market – By Route of Administration

1.3.3 North America Metastatic Cancer Drugs Market – By Drug Class

1.3.4 North America Metastatic Cancer Drugs Market – By Product

1.3.5 North America Metastatic Cancer Drugs Market – By End User

1.3.6 North America Metastatic Cancer Drugs Market – By Country

2. North America Metastatic Cancer Drugs Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Metastatic Cancer Drugs Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America– PEST Analysis

4.3 Expert Opinion

5. North America Metastatic Cancer Drugs Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 High Prevalence of Metastatic Cancer

5.1.2 Government Initiatives to Support Developments in Cancer Treatment

5.2 Market Restraints

5.2.1 High Cost of Oncology Drugs

5.3 Market Opportunities

5.3.1 Investments in Artificial Intelligence for Oncology Drug Development

5.4 Future Trends

5.4.1 Increase in Launch of Metastatic Cancer Drugs

5.5 Impact analysis

6. North America Metastatic Cancer Drugs Market – Country Analysis

6.1 North America Metastatic Cancer Drugs Market Revenue Forecast and Analysis

7. North America Metastatic Cancer Drug Market Analysis – By Cancer Type

7.1 Overview

7.2 North America Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)

7.2.1 North America: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

7.3 Breast Cancer

7.3.1 Overview

7.3.2 Breast Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Lung Cancer

7.4.1 Overview

7.4.2 Lung Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Liver Cancer

7.5.1 Overview

7.5.2 Liver Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.6 Hematological Cancer

7.6.1 Overview

7.6.2 Hematological Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.7 Brain Cancer

7.7.1 Overview

7.7.2 Brain Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.8 Prostate Cancer

7.8.1 Overview

7.8.2 Prostate Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.9 Pancreatic Cancer

7.9.1 Overview

7.9.2 Pancreatic Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.10 Others

7.10.1 Overview

7.10.2 Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8. North America Metastatic Cancer Drug Market – By Route of Administration

8.1 Overview

8.2 North America Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)

8.2.1 North America: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

8.3 Intravenous

8.3.1 Overview

8.3.2 Intravenous: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Intramuscular

8.4.1 Overview

8.4.2 Intramuscular: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Oral

8.5.1 Overview

8.5.2 Oral: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Others

8.6.1 Overview

8.6.2 Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Metastatic Cancer Drug Market – By Drug Class

9.1 Overview

9.2 North America Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)

9.2.1 North America: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

9.3 HER2 Inhibitors

9.3.1 Overview

9.3.2 HER2 Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Immune Checkpoints Inhibitors

9.4.1 Overview

9.4.2 Immune Checkpoints Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.5 PARP Inhibitors

9.5.1 Overview

9.5.2 PARP Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.6 Kinase Inhibitors

9.6.1 Overview

9.6.2 Kinase Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.7 Others

9.7.1 Overview

9.7.2 Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

10. North America Metastatic Cancer Drug Market – By Product

10.1 Overview

10.2 North America Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)

10.2.1 North America: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

10.3 Branded

10.3.1 Overview

10.3.2 Branded: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

10.4 Generics and Biosimilars

10.4.1 Overview

10.4.2 Generics and Biosimilars: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11. North America Metastatic Cancer Drug Market – By End User

11.1 Overview

11.2 North America Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)

11.2.1 North America: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

11.3 Hospital

11.3.1 Overview

11.3.2 Hospitals: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11.4 Specialty Clinic

11.4.1 Overview

11.4.2 Specialty Clinics: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11.5 Others

11.5.1 Overview

11.5.2 Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

12. North America Metastatic Cancer Drugs Market – Regional Analysis

12.1 North America Metastatic Cancer Drugs Market Revenue Forecast and Analysis

12.1.1 North America Metastatic Cancer Drugs Market Revenue Forecast and Analysis

12.1.1.1 US: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.1 US: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.2 US: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.3 US: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.4 US: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.5 US: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

12.1.1.1.6 US: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

12.1.1.2 Canada: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.2.1 Canada: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.2.2 Canada: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

12.1.1.2.3 Canada: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

12.1.1.2.4 Canada: North America Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

12.1.1.2.5 Canada: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

12.1.1.2.6 Canada: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

12.1.1.3 Mexico: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.3.1 Mexico: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.1.3.2 Mexico: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

12.1.1.3.3 Mexico: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

12.1.1.3.4 Mexico: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

12.1.1.3.5 Mexico: North America Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

12.1.1.3.6 Mexico: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

13. North America Metastatic Cancer Drug Market –Industry Landscape

13.1 Overview

13.2 Growth Strategies in the North America Metastatic Cancer Drug Market, 2021-2028

13.3 Inorganic Developments

13.3.1 Overview

13.4 Organic Growth Strategies

13.4.1 Overview

14. Company Profiles

14.1 AbbVie Inc.

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Amgen Inc.

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Bristol-Myers Squibb Company

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 F. HOFFMANN-LA ROCHE LTD.

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 Novartis AG

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Astrazeneca

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 Eli Lilly and Company.

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 MERCK KGaA

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 Pfizer Inc. (Arena Pharmaceutical GmbH)

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

14.10 Johnson and Johnson Services, Inc.

14.10.1 Key Facts

14.10.2 Business Description

14.10.3 Products and Services

14.10.4 Financial Overview

14.10.5 SWOT Analysis

14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners

15.2 Glossary of Terms

LIST OF TABLES.

Table 1. North America: North America Metastatic Cancer Drug Market, – Revenue and Forecast to 2028 (USD Million)

Table 2. North America: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 3. North America: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 4. North America: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 5. North America: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 6. North America: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 7. US: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 8. US: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 9. US: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 10.   US: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 11.   US: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 12.   Canada: North America Metastatic Cancer Drug Market, by Cancer Type - Revenue and Forecast to 2028 (USD Million)

Table 13.   Canada: North America Metastatic Cancer Drug Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)

Table 14.   Canada: North America Metastatic Cancer Drug Market, by Drug Class - Revenue and Forecast to 2028 (USD Million)

Table 15.   Canada: North America Metastatic Cancer Drug Market, by Product - Revenue and Forecast to 2028 (USD Million)

Table 16.   Canada: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 17.   Mexico: North America Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 18.   Mexico: North America Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 19.   Mexico: North America Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 20.   Mexico: North America Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 21.   Mexico: North America Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 22.   Recent Inorganic Growth Strategies in the North America Metastatic Cancer Drug Market

Table 23.   Recent Organic Growth Strategies in the North America Metastatic Cancer Drug Market

Table 24.   Glossary of Terms, North America Metastatic Cancer Drugs Market

LIST OF FIGURES.

Figure 1. North America Metastatic Cancer Drugs Market Segmentation

Figure 2. North America Metastatic Cancer Drugs Market Overview

Figure 3. The PARP Inhibitors Segment Held The Largest Share of Drug Class Segment in North America Metastatic Cancer Drugs Market

Figure 4. US Is Expected to Show Remarkable Growth During the Forecast Period

Figure 5. North America PEST Analysis

Figure 6. Expert Opinion

Figure 7. North America Metastatic Cancer Drugs Market Impact Analysis of Driver and Restraints

Figure 8. North America Metastatic Cancer Drugs Market – Revenue Forecast and Analysis – 2021- 2028

Figure 9. North America Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)

Figure 10.   Breast Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 11.   Lung Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12.   Liver Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.   Hematological Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.   Brain Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15.   Prostate Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.   Pancreatic Cancer: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.   Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.   North America Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)

Figure 19.   Intravenous: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20.   Intramuscular: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.   Oral: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.   Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.   North America Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)

Figure 24.   HER2 Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.   Immune Checkpoints Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.   PARP Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27.   Kinase Inhibitors: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28.   Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.   North America Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)

Figure 30.   Branded: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31.   Generics and Biosimilars: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32.   North America Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)

Figure 33.   Hospitals: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34.   Specialty Clinics: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 35.   Others: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36.   North America Metastatic Cancer Drugs Market – By Country Forecast and Analysis – 2021- 2028.

Figure 37.   North America: North America Metastatic Cancer Drug Market, by Key Country – Revenue (2021) (USD Million)

Figure 38.   US: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 39.   Canada: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 40.   Mexico: North America Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 41.   Growth Strategies in the North America Metastatic Cancer Drug Market, 2021-2028

The List of Companies - North America Metastatic Cancer Drugs Market

● AbbVie Inc.                                                                                                        

● Amgen Inc.                                                                                                         

● Bristol-Myers Squibb Company                                                                 

● F. HOFFMANN-LA ROCHE LTD.                                                                   

● Novartis AG                                                                                                       

● Astrazeneca                                                                                                      

● Eli Lilly and Company                                                                                     

● MERCK KGaA                                                                                                    

● Pfizer Inc. (Arena Pharmaceutical GmbH)                                             

● Johnson and Johnson Services, Inc.

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Metastatic Cancer Drugs Market.

● Highlights key business priorities in order to assist companies to realign their business strategies.

● The key findings and recommendations highlight crucial progressive industry trends in North America Metastatic Cancer Drugs Market, thereby allowing players across the value chain to develop effective long-term strategies.

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.

● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TOP